ATAI Life Sciences Archives

Psychedelics News

ATAI Life Sciences

Industry

3 Oct 2023

atai Life Sciences Completes Phase 1 Study of Oral DMT

Atai Life Sciences has completed its Phase 1 study of VLS-01, an oral DMT for treatment-resistant depression (TRD)....

By Jason Najum

Breaking News

10 Aug 2023

Christian Angermayer Gives Insight on Future of Atai’s Ketamine Program

Christain Angermayer gave some clarification on PCN-101, atai's ketamine program, hinting at new direction for the compound....

By Jason Najum

Breaking News, Industry

9 Aug 2023

atai Life Sciences Announces Results of New Phase 1 Study of PCN-101 (R-Ketamine)

Atai announced results from Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine)....

By Microdose NewsDesk

Finance

11 May 2023

atai Life Sciences Reports Q1 2023 Financial Results and Highlights

atai Life Sciences has released its First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates...

By Microdose NewsDesk

Join Our Newsletter for Exclusive Updates, Stories, and More

Science

28 Apr 2023

atai Life Sciences Presents Phase 1 Study Data on GRX-917

Earlier this year, atai Life Science company GABA Therapeutics announced Positive Final Results from Phase 1 trial of GRX-917....

By Jason Najum

Industry

18 Apr 2023

Atai Partner IntelGenx Announces FDA Approval of Oral Film

Under-the-radar firm IntelGenx has just received FDA approval....

By Microdose NewsDesk

Industry

14 Apr 2023

Atai Starts New Phase 1 Study of PCN-101 (R-Ketamine)

Back in January, atai Life Sciences released results for its most advanced program: PCN-101 (using R-Ketamine for Treatment-Resistant Depression) Unfortunately for patients and investors, results were somewhat disappointing and “did...

By Microdose NewsDesk

Finance

3 Apr 2023

Chrisitian Angermayer Shows Faith in Atai, Buys Another 1.2 M Shares

On March 29th, Christian Angermayer, Founder and Chairman of atai Life Sciences (Nasdaq: ATAI), announced that he was buying more shares of the psychedelic medicines and biotechnology company....

By James Hallifax

Industry

29 Mar 2023

Atai CEO Answers Questions From the Public

Reddit is the internet incarnate....

By Microdose NewsDesk

Follow us on social

Latest News

AbbVie Withdraws Patent Challenge, Clearing Path for Enveric’s Psychedelic IP Strategy

Breaking: Enveric Reports New Mechanistic Data Supporting Non-Hallucinogenic Neuroplastogen Strategy

Two New Studies Are Rewriting the Rules of Psychedelic Drug Development

Professional Training in Psychedelic Medicine

Psychedelic medicine is reshaping the future of mental health care. From the power of microdosing LSD to the promise of MDMA in PTSD, the world of medical psychedelics offers transformative possibilities. Our comprehensive, CE-accredited course provides you with the knowledge and understanding you need to tap into this groundbreaking field.

WordPress Ads

No Result

View All Result